Neurosurgery has spent decades removing things.
For the first time, we're looking to add something back.
Configurable, physician-monitored closed-loop neuromodulation for drug-resistant epilepsy. Built to detect, predict, and arrest seizures in real time, entirely on-device. Our rodent pipeline demonstrates a median 62% seizure reduction at 3-month treatment.
Validated at Yale School of Medicine using a custom closed-loop recording and stimulation toolchain. We are now moving to primate studies.
Despite 40 years and 30+ drugs, the 1-in-3 drug-resistant rate has not moved. New drugs like cenobamate help some patients, but a large persistent population remains unreachable by pharmacology alone. Non-invasive technologies like focused ultrasound are promising but remain in Phase I trials with no FDA approval for epilepsy. For this population, closed-loop implantable neuromodulation is the only evidence-backed solution available today.
Despite approximately 30 licensed anti-seizure medications, the proportion of drug-resistant patients has remained at 30–40% since 1982. New drugs treat symptoms, not causes. Tolerance and cross-resistance mean the ceiling is structural, not incremental.
Kwan et al., JAMA Neurology 2018 ↗Focused ultrasound (tFUS) is in Phase I safety trials today. Realistically, FDA approval for epilepsy is a decade away at minimum. More importantly, even an approved tFUS device will not serve the full drug-resistant population.
Premaratne et al., J. Neurology 2025 ↗Responsive neurostimulation and closed-loop DBS are FDA-approved and reduce seizures in patients who have exhausted all other options. For refractory epilepsy, implantable devices represent the last and most effective intervention available before irreversible outcomes set in.
NeuroPace RNS FDA Approval ↗Book a demo and download our open-source hardware stack. Built for seizure treatment verification.
We aim to research and design silicon and packaging solutions that shift from fixed-function to general-purpose architectures, tackling larger amounts of neural throughput under stringent FDA power constraints. Long-term, we are exploring the tapeout of small-parameter AI models directly onto neural silicon.
The only reconfigurable BCI with full on-chip compute
and closed-loop capability.
| neuræ | Medtronic | NeuroPace | Aziz | Kassiri | Neuralink | NURIP | Blackrock | Synchron | |
|---|---|---|---|---|---|---|---|---|---|
| Tasks Supported | |||||||||
| Spike Detection | ✓ | ✕ | ✕ | ✕ | ✕ | ✕ | ✕ | ✓ | ✕ |
| Compression | ✓ | ✕ | ✕ | ✓ | ✕ | ✕ | ✕ | ✕ | ✕ |
| Seizure Prediction | ✓ | ✕ | ✓ | ✕ | ✓ | ✕ | ✓ | ✕ | ✕ |
| Movement Intent | ✓ | ✓ | ✕ | ✕ | ✕ | ✕ | ✕ | ✕ | ✓ |
| Encryption | ✓ | ✕ | ✕ | ✕ | ✕ | ✕ | ✕ | ✕ | ✕ |
| Technical Capabilities | |||||||||
| Programmable | ✓ | ✓ | Limited | ✕ | ✓ | ✕ | Limited | Limited | ✕ |
| Read Channels | 96 | 4 | 8 | 256 | 24 | 3072 | 32 | 96 | 16 |
| Data Rate (Mbps) | 46 | 0.01 | 0.02 | 9.76 | 1.32 | 545 | 0.13 | 30 | 0.5 |
| Power (mW) | 15 | 2 | 6.5 | 12 | 8 | 20 | 10 | 15 | 10 |
| Safety (<15 mW) | ✓ | ✓ | ✓ | ✓ | ✓ | ✕ | ✓ | ✓ | ✓ |
| Architecture | GALS | Fixed | Fixed | Fixed | Reconfig. | Fixed | Fixed | Fixed | Fixed |
| Processing | |||||||||
| On-chip Processing | Full | Limited | Limited | ✕ | Limited | ✕ | Limited | ✕ | Limited |
| Closed-loop | ✓ | ✓ | ✓ | ✕ | ✓ | ✕ | ✓ | ✕ | ✕ |
We're working with select neurology centers, research labs, and neurotech investors.